MedTrace Logo

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

NCT05214612 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-07-31

No results posted yet for this study

Summary

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG.

This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Conditions

  • Myasthenia Gravis
  • Autoimmune Diseases of the Nervous System
  • Neuromuscular Junction Diseases
  • Thymoma
  • Thymus Hyperplasia
  • Nervous System Diseases
  • Myasthenia Gravis, Generalized
  • Myasthenia Gravis, Ocular
  • Myasthenia Gravis Crisis
  • Myasthenia Gravis With Exacerbation (Disorder)
  • Myasthenia Gravis, Adult Form
  • Myasthenia Gravis, Juvenile Form

Interventions

COMBINATION_PRODUCT

Drug treatment of myasthenia gravis and treatment of crisis

Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05214612 on ClinicalTrials.gov